Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Visceral obesity is associated with increased left ventricular mass and reduced ventricular volumes — suggesting concentric ...

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

A study by researchers at the Federal University of São Carlos (UFSCar) in Brazil, in partnership with University College ...

Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

Soybean oil, used for cooking in more than half of American households, is linked to a higher risk of obesity in a new study.

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Obesity accelerates the rise of Alzheimer’s-related blood biomarkers far more rapidly than previously recognized. Long-term imaging and plasma data show that obese individuals experience much faster ...

The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health ...